Want to monitor TOVX?
Get notified when price crosses targets, volume spikes, or RSI hits oversold
Create free account to monitor TOVXsynthetic biologics, inc. (nyse mkt: syn) is a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients. the company's lead candidates poised for phase 3 development are: (1) syn-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (ibs-c), and (2) syn-004 (ribaxamase) which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (iv) beta-lactam antibiotics for the prevention of c.